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ABSTRACT 23 
Urolithin A is a major metabolite produced by rats and humans after consumption of 24 
pomegranate juice or pure ellagitannin geraniin. In this study, we investigated the 25 
anti-inflammatory effect of urolithin A on carrageenan-induced paw edema in mice. The 26 
volume of paw edema was reduced at 1 h after oral administration of urolithin A. In 27 
addition, plasma in treated mice exhibited significant oxygen radical antioxidant 28 
capacity (ORAC) scores with high plasma levels of the unconjugated form at 1 h after 29 
oral administration of urolithin A. These results indicate strong associations among 30 
plasma urolithin A levels, the plasma ORAC scores, and anti-inflammatory effects and 31 
may help explain a mechanism by which ellagitannins confer protection against 32 
inflammatory diseases. 33 
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Ellagitannins are natural antioxidants, which are found in many medicinal plants 41 
and foods such as pomegranates, raspberries, blackberries, and walnuts.1 Various 42 
biological studies of ellagitannins have demonstrated antioxidant,2 antiviral,3 43 
antimutagenic,4 antimicrobial,5-7 anti-inflammatory,8 and antitumor activities9-10 and the 44 
absorption and metabolism of ellagitannins have recently been reported in animal and 45 
human studies. Consumption of ellagitannin-rich beverages, such as pomegranate juice, 46 
results in the production of ellagitannin metabolites, ellagic acid and 47 
3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one (urolithin A) (Fig. 1).11-14 Furthermore, we 48 
have isolated and characterized seven urinary and gut microbial metabolites in rats 49 
including urolithin A after the ingestion of geraniin, which is a typical ellagitannin 50 
found in Geranium thunbergii.15 Urolithin A has been found to be the main metabolite 51 
in plasma after the administration of geraniin in rats16 and pomegranate juice in 52 
humans13 and it is the most potent antioxidant among major ellagitannin metabolites.16 53 
Free radical-mediated peroxidation of membrane lipids and oxidative damage of 54 
DNA are involved in a variety of pathological complications such as cancer, 55 
atherosclerosis, and neurodegenerative diseases. Because of their antioxidant activity, 56 
ellagitannins may play a vital role in protecting against these oxidative stress-mediated 57 
pathological conditions. We previously reported that urolithin A exhibited more potent 58 
antioxidant activity than intact ellagitannins, as indicated by oxygen radical absorbance 59 
capacity (ORAC) measurements, suggesting that urolithin A may be a key mediator of 60 
ellagitannin protection. In addition, because oxidative stress plays an important role in 61 
the pathogenesis of inflammation, the ability of antioxidants to scavenge reactive 62 
oxygen species (ROS) may also provide anti-inflammatory activity. Specifically, ellagic 63 
acid, an ellagitannin metabolite, has been shown to inhibit activated biomarkers of 64 
4 
 
inflammation, such as tumor necrosis factor-α and interleukin (IL)-1β.17 Recently, 65 
urolithin A has been shown to inhibit prostaglandin E2 production induced by IL-1β18 66 
and attenuate the effect of colonic inflammation in a colitis rat model.19 In the present 67 
study, we investigated in vivo anti-inflammatory and antioxidant properties of the 68 
ellagitannin metabolite urolithin A in a carrageenan-induced paw edema model in 69 
mice20 and with an ORAC assay in order to clarify the possible role of ellagitannin 70 
metabolites as biological antioxidants after consumption of ellagitannins. 71 
Carrageenan-induced inflammation is a useful model to evaluate the effect of 72 
potential anti-inflammatory agents after oral administration.21 Paw edema was induced 73 
in the right hind paw of ICR mice by the subcutaneous injection of 1% λ-carrageenan in 74 
physiological saline (50 μL). The inflammation level was quantified by the volume of 75 
paw edema. Urolithin A prepared by chemical synthesis15 in 0.5% 76 
carboxymethylcellulose suspension was orally administered to the mice at 1 or 6 h 77 
before carrageenan injection. The anti-inflammatory effects of urolithin A on 78 
carrageenan-induced edema in mice are summarized in Fig. 2. The volume of paw 79 
edema of mice treated with urolithin A at 1 h before carrageenan injection decreased to 80 
35%, 26%, and 34% relative to the control group after 3, 6, and 24 h of inflammatory 81 
induction, respectively (Fig. 2A). The differences in mean values of the control group 82 
were statistically significant at p < 0.05; however, treatment with urolithin A at 6 h 83 
before inflammatory induction by carrageenan showed no effect (Fig. 2B). The edema 84 
induced by carrageenan injection is believed to be biphasic in nature. The initial phase, 85 
beginning 1 h after carrageenan administration, is due to the release of histamine and 86 
serotonin. The second phase, occurring 2 to 5 h after carrageenan ingestion, is induced 87 
by the release of bradykinin, proteases, prostaglandin, and lysozyme.22 Our data suggest 88 
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that treatment with urolithin A at 1 h before inflammatory induction is effective on both 89 
phases of inflammation induced by carrageenan.  90 
Peripheral inflammatory responses have been mechanistically linked to enhanced 91 
production of ROS, such as superoxide anion, peroxynitrite anion, hydroxyl radical, and 92 
hydrogen peroxide radical, at the inflamed site.23 Systematic comparison studies on the 93 
antioxidant and anti-inflammatory effects of phytochemicals have recently been 94 
performed.24-26 Natural antioxidants such as polyphenols may protect against 95 
oxidant-mediated inflammation and tissue damage by their ability to scavenge free 96 
radicals. The antioxidant capacity of urolithin A proved more potent than that of the 97 
intact ellagitannins, such as geraniin and corilagin, as measured by the ORAC assay,16 98 
so that urolithin A is predicted to directly contribute to suppression of 99 
carrageenan-induced inflammation after oral administration. The ORAC method is 100 
based on the inhibition of peroxyl radical-induced oxidation and has the advantage of 101 
utilizing a biologically relevant radical source.27-28  102 
We investigated the association between the plasma ORAC scores and plasma 103 
levels after oral administration of urolithin A in mice. Mouse plasma samples collected 104 
at 1 h and 6 h after administration were employed for the ORAC assay29 and estimation 105 
of plasma urolithin A levels.30 The ORAC scores were increased to 142% in plasma of 106 
mice at 1 h after administration compared to those of control plasma samples obtained 107 
before administration (Fig. 3). The scores were reduced to 118% of the control scores at 108 
6 h.  109 
Plasma levels of urolithin A analyzed by the HPLC-ESI-MS/MS method are 110 
shown in Table 1. Total urolithin A levels reached 3.9 μM at 1 h after ingestion and 111 
decreased to 1.3 μM at 6 h. On the other hand, the related metabolite, 112 
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3-hydroxy-6H-dibenzo[b,d]pyran-6-one (urolithin B) (Fig. 1), which may be a gut 113 
microbial metabolite derived from urolithin A in mammals,31 could not be detected in 114 
any plasma samples. We recently demonstrated that urolithin A plasma levels in rats 115 
reached a maximum of 0.45 μM at 6 h after ingestion of 5 mg/head of ellagitannin 116 
geraniin.16 Furthermore, Seeram et al. reported that plasma levels of urolithin A in 117 
humans reached 0.04 μM and 0.11 μM at 0.5 h and 6 h, respectively, after consumption 118 
of pomegranate juice (180 mL containing ellagitannin punicalagin 318 mg).13 Both 119 
studies revealed that plasma levels of the main metabolite, urolithin A, reached 120 
maximum values 6 h after consumption of pure ellagitannin or pomegranate juice. In 121 
this study, we were the first to demonstrate that urolithin A was rapidly absorbed and 122 
had good bioavailability after oral administration.  123 
Most of the polyphenolic compounds present in the blood circulatory system exist 124 
in conjugated forms, such as glucuronide and sulfate, so that biological activity of some 125 
conjugates are believed to be reduced compared to free form. In a tandem mass 126 
spectrometry, the bonds of glucuronides and sulfates are easily cleaved in the collision 127 
cell to generate product ions of [M-H-176]− and [M-H-80]− respectively, which 128 
correspond to the fragments resulting from the deprotonated molecule. The neutral loss 129 
scan is a powerful tool for identifying the existence of conjugated forms in biofluids. 130 
For detection of urolithin A conjugates in mouse plasma, neutral loss scans were 131 
performed for glucuronide and sulfates (Fig. 4). The peak due to glucuronide was 132 
observed at 2.5 min in the neutral loss of 176 dalton scan data (Fig. 4A) and the mass 133 
spectrum of the peak at 2.5 min showed the ion peak at m/z 403, corresponding to 134 
urolithin A monoglucuronide (Fig. 4B). The peak corresponding to sulfates could not be 135 
detected in any plasma samples.  136 
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Plasma levels of free urolithin A were estimated by treatment with and without 137 
β-glucuronidase, and it was determined that urolithin A was present as free form in 138 
77.2% and 65.7% of the plasma samples at 1 h and 6 h after administration, respectively 139 
(Table 1). Lysosomal enzymes, including β-glucuronidase, are released from 140 
inflammatory cells such as neutrophils and macrophages at the inflammatory site. Some 141 
flavonoid glycosides have been reported to be deconjugated into aglycone by 142 
β-glucuronidase released from neutrophils after the induction of inflammation.32-33 143 
Urolithin A glucuronide in plasma may also serve to reduce the inflammation after 144 
deconjugation at the inflamed site. Our findings indicate a strong association among 145 
plasma urolithin A levels, the plasma ORAC scores, and anti-inflammatory effects in 146 
the carrageenan-induced paw edema mice model. Thus, the potent antioxidant capacity 147 
of urolithin A in mouse plasma may contribute to the anti-inflammatory response at the 148 
affected sites after oral administration. 149 
In this study, we investigated anti-inflammatory activity in the 150 
carrageenan-induced paw edema mice model and in vivo antioxidant activity of 151 
urolithin A. Our data indicate that urolithin A has profound anti-inflammatory effects, 152 
which are associated with the significant ORAC scores and high plasma levels of free 153 
urolithin A at 1 h after oral administration. These findings suggest that urolithin A as an 154 
antioxidative metabolite of ellagitannins may contribute to the prevention of 155 
inflammatory diseases after oral administration and could help explain the protective 156 
effects of ellagitannin consumed from natural sources.  157 
158 
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Figure Legends 273 
 274 
Figure 1.  Chemical structures of urolithins A and B. 275 
 276 
Figure 2.  Anti-inflammatory effects of urolithin A on paw edema induced by 277 
carrageenan in mice at 1 (A) and 6 (B) h after oral administration. Data are expressed as 278 
means of the difference between the final and initial volumes ± SEM (n = 10). Mean 279 
value was significantly different from control: *p < 0.05. 280 
 281 
Figure 3.  Plasma Oxygen Radical Absorbance Capacity (ORAC) scores after urolithin 282 
A intake by mice. Data are expressed as means ± SEM (n = 7–10). Mean value was 283 
significantly different from the value at 0 h: **p < 0.01.  284 
 285 
Figure 4.  Neutral loss scan data of (A) 176 dalton for glucuronide form of urolithin A 286 
obtained using HPLC-ESI-MS/MS method and (B) mass spectrum of the peak at 2.5 287 
min containing urolithin A monoglucuronide at m/z 403. 288 
 289 
15 
 
Table 1  
Plasma levels of total or free urolithin A treated with or without β-glucuronidasea 
Time  
(h) 
Total urolithin A 
(μM) 
Free urolithin A 
(μM) 
Percentage of free 
urolithin A (%)b 
1 3.88 ± 0.25 2.85 ± 0.32 77.2 ± 10.9 
6 1.27 ± 0.06 0.83 ± 0.05 65.7 ± 4.4 
a Data are expressed as means ± SEM (n = 5–10) 
b Free urolithin A / total urolithin A × 100 
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